Your Patient Can't Fill Their Esterified Estrogens/Methyltestosterone Prescription — Now What?

It's a scenario playing out in clinics across the country: your menopausal patient, well-controlled on Esterified Estrogens/Methyltestosterone (EEMT), calls or messages to report that their pharmacy can't fill the prescription. Maybe they've already tried two or three locations. Their hot flashes are returning. They need help.

As a provider, you're in a unique position to help — but only if you have the right tools and strategies at your disposal. This guide lays out a practical, step-by-step approach to help your patients locate their medication, navigate insurance barriers, and maintain continuity of care.

Current Availability: What You Need to Know

Esterified Estrogens/Methyltestosterone is not formally listed on the FDA Drug Shortage Database as of 2026, but functionally, it behaves like a drug in shortage. Key factors affecting availability:

• Limited generic manufacturers: Only a handful of companies produce EEMT and EEMT HS
• No remaining brand-name products: Estratest, Covaryx, Essian, and Menogen have all been discontinued
• Controlled substance classification: DEA Schedule III status adds production and distribution complexity
• Pre-NDA regulatory status: The product was never approved through the modern FDA pathway, deterring new market entrants

For a comprehensive supply analysis, see our provider shortage briefing.

Why Patients Can't Find It

Understanding the root causes helps you counsel patients effectively:

1. Chain pharmacy stocking decisions: Large chains prioritize shelf space for high-volume medications. A niche product like EEMT may not meet stocking thresholds at many locations.
2. Wholesaler allocation: When supply is limited, wholesalers may allocate available inventory to pharmacies with established ordering history for the product. New pharmacy requests may be deprioritized.
3. Regional variability: Availability can vary significantly by geography. A pharmacy 20 miles away may have stock when the one next door doesn't.
4. Strength confusion: Patients may not realize there are two strengths (full strength 1.25 mg/2.5 mg and half strength 0.625 mg/1.25 mg). A pharmacy may have one but not the other.

5 Steps Providers Can Take to Help

Step 1: Check Real-Time Pharmacy Availability

Medfinder for Providers lets your team check which pharmacies near your patient currently have Esterified Estrogens/Methyltestosterone in stock. This takes seconds and eliminates the guesswork of sending prescriptions to pharmacies that may not carry the product.

Workflow tip: Before e-prescribing, have your staff check Medfinder to verify the receiving pharmacy has the medication available. This prevents prescription bouncing and reduces patient frustration.

Step 2: E-Prescribe to the Right Pharmacy

Once you've identified a pharmacy with stock, send the prescription directly there. If your patient's usual pharmacy doesn't carry EEMT:

• Send a new prescription to the stocked pharmacy (preferred for controlled substances)
• Or coordinate a prescription transfer if state law permits for Schedule III medications (most states allow one transfer)

For ongoing supply, help the patient establish a relationship with a pharmacy that regularly stocks the medication — often an independent pharmacy.

Step 3: Consider Independent and Compounding Pharmacies

Independent pharmacies are often more flexible than chains in sourcing niche medications. Benefits include:

• Multiple wholesaler relationships for broader sourcing
• Willingness to special-order for individual patients
• More personalized pharmacist-patient relationships

Compounding pharmacies offer an additional safety net. If the commercial product is truly unavailable, a compounding prescription can provide an equivalent preparation. When writing a compounding prescription:

• Specify: Esterified Estrogens [dose] + Methyltestosterone [dose] (or bioidentical testosterone if preferred)
• Include: dosage form (oral capsule), quantity, refills, and dosing schedule
• Use a PCAB-accredited compounding pharmacy when possible

Step 4: Leverage Mail-Order and Specialty Pharmacies

Insurance-affiliated mail-order pharmacies often maintain larger inventories than retail locations. For patients with stable prescriptions, a 90-day mail-order supply can provide:

• Better availability (larger distribution centers)
• Potential cost savings (90-day supply at lower per-unit cost)
• Convenience (home delivery)

Help your patient contact their insurance plan to determine mail-order eligibility for this controlled substance.

Step 5: Document and Communicate Insurance Barriers

If insurance is part of the problem (prior authorization, step therapy requirements, or formulary exclusion), your office can facilitate:

• Prior authorization: Submit supporting documentation that the patient has tried estrogen-alone therapy without adequate response (this is the clinical basis for this combination product)
• Step therapy override: If the plan requires trying alternatives first, document the patient's clinical history with estrogen monotherapy failure
• Formulary exception: Appeal for coverage if the medication is excluded from the patient's formulary, citing medical necessity

Alternatives to Consider

When Esterified Estrogens/Methyltestosterone simply cannot be sourced, these alternatives are clinically reasonable:

• Estradiol (oral, transdermal, or topical) ± progestogen: First-line for most menopausal vasomotor symptoms. Transdermal delivery may offer a better cardiovascular risk profile.
• Prempro / Premphase: Conjugated estrogens + medroxyprogesterone. Good option for women with a uterus who need combined therapy.
• Bijuva: Bioidentical estradiol + progesterone. FDA-approved combination for vasomotor symptoms.
• Estrogen therapy + off-label testosterone: For patients who specifically need the androgen component. Options include compounded testosterone cream, off-label testosterone pellets, or low-dose testosterone preparations.

For a patient-friendly version of this information, share our alternatives guide with your patients.

Workflow Tips for Your Practice

• Flag patients on EEMT in your EHR to proactively manage supply issues before they become urgent
• Maintain a list of local pharmacies that reliably stock EEMT, including at least one independent and one compounding pharmacy
• Create a standard prior authorization template for this medication to reduce administrative burden when insurance denials occur
• Educate patients proactively about the supply situation and backup plans during their appointments — don't wait until they're out of medication
• Bookmark Medfinder for Providers as a staff resource for real-time pharmacy availability checks

Final Thoughts

The Esterified Estrogens/Methyltestosterone availability challenge isn't going away soon, but with the right strategies, you can minimize its impact on patient care. Proactive planning, real-time availability tools, and familiarity with alternatives are your best tools for keeping patients treated and satisfied.

For additional provider resources and real-time medication availability data, visit medfinder.com/providers.

For the patient perspective on this issue, see our patient guide to finding Esterified Estrogens/Methyltestosterone in stock.